首页> 美国卫生研究院文献>Scientific Reports >Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects
【2h】

Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects

机译:全面的孕产妇血清蛋白质组学将细胞骨架蛋白鉴定为先天性心脏缺陷的产前诊断中的非侵入性生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Congenital heart defects (CHDs) are the most common group of major birth defects. Presently there are no clinically used biomarkers for prenatally detecting CHDs. Here, we performed a comprehensive maternal serum proteomics assessment, combined with immunoassays, for the discovery of non-invasive biomarkers for prenatal diagnosis of CHDs. A total of 370 women were included in this study. An isobaric tagging for relative and absolute quantification (iTRAQ) proteomic approach was used first to compare protein profiles in pooled serum collected from women who had CHD-possessing or normal fetuses, and 47 proteins displayed significant differential expressions. Targeted verifications were performed on 11 proteins using multiple reaction monitoring mass spectrometry (MRM-MS), and the resultant candidate biomarkers were then further validated using ELISA analysis. Finally, we identified a biomarker panel composed of 4 cytoskeletal proteins capable of differentiating CHD-pregnancies from normal ones [with an area under the receiver operating characteristic curve (AUC) of 0.938, P < 0.0001]. The discovery of cytoskeletal protein changes in maternal serum not only could help us in prenatal diagnosis of CHDs, but also may shed new light on CHD embryogenesis studies.
机译:先天性心脏缺陷(CHD)是最常见的主要出生缺陷组。目前,尚无可用于产前检测冠心病的临床生物标志物。在这里,我们进行了全面的产妇血清蛋白质组学评估,并结合了免疫分析方法,以发现可用于产前诊断冠心病的非侵入性生物标志物。本研究共纳入370名妇女。首先使用等压相对和绝对定量标签(iTRAQ)蛋白质组学方法比较从患有CHD或正常胎儿的妇女收集的混合血清中的蛋白质谱,其中47种蛋白质表现出显着的差异表达。使用多反应监测质谱(MRM-MS)对11种蛋白质进行了有针对性的验证,然后使用ELISA分析进一步验证了所得的候选生物标志物。最后,我们确定了一种由4种能够区分CHD妊娠与正常妊娠的细胞骨架蛋白组成的生物标志物组[受体工作特征曲线下的面积(AUC)为0.938,P <0.0001]。母体血清中细胞骨架蛋白变化的发现不仅可以帮助我们在产前诊断冠心病,也可以为冠心病的胚胎发生研究提供新的思路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号